Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3041-3050 Newer>

Managed Care July 2006 John Marcille	From the Grass Roots, A Demand for Health Security Fallout from the Medicare Modernization Act promises to rain down for years to come.
Managed Care July 2006	AMA Lays Down Guidelines For Retail Clinics The American Medical Association came out with nine guidelines that the organization suggests store-based clinics follow. Not surprisingly, the rules stipulate a doctor's role in such a clinic. Here are some of those guidelines.
Managed Care July 2006	Specialty Anti-Inflammatories See Huge Increase in Utilization Americans spent 34% more for specialty anti-inflammatory agents used to treat rheumatoid arthritis in 2005 than any other specialty drug category.
Managed Care July 2006	Public Payers Foot Greater Pharmacy Costs Through 2005, private health insurance had covered most of the cost of prescription drugs. That picture is changing as public payments, mostly under Part D, are projected to exceed private health insurance and out-of-pocket payments.
The Motley Fool July 28, 2006 Jack Uldrich	Tiny Particles Cause a Big Storm for Abraxis Elan sues Abraxis Bioscience for patent infringement. Abraxis' stock, which has fallen nearly 60% from its 52-week high, might make a compelling buy for more risk-tolerant investors.
The Motley Fool July 27, 2006 Brian Lawler	Aspreva's One-Drug Wonder With rapidly growing royalties from CellCept, and the potential to expand the drug into new indications, shares of Aspreva are attractive at current levels, as long as the company does not make any bad acquisitions with its cash hoard.
BusinessWeek July 31, 2006 Arlene Weintraub	It's On The Tip Of Your Tongue As more medicines take the form of "edible film," the market is exploding.
The Motley Fool July 26, 2006 Brian Lawler	Biogen Slows Down Several potential growth drivers should help the biopharma. Ever since the merger with Idec, the company has been fairly well run (absent the Tysabri delays). Investors, take note.
The Motley Fool July 26, 2006 Ryan Fuhrmann	HMA Is Sickly The HCA bid could confirm that negative hospital industry trends have reached their peak. HMA CEO Joseph Vumbacco also confirmed that his company was not in talks with private equity firms, not that the stock moved up in hopes that a deal was on the horizon.
Chemistry World July 25, 2006 Bea Perks	Clinical Chaos Under Scrutiny Clinical trials of new drugs need to be tightened up, according to an expert group convened in the aftermath of UK trials that left six people fighting for their lives.
<Older 3041-3050 Newer> Return to current articles.